Clinical Trial Detail

NCT ID NCT02105636
Title Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Bristol-Myers Squibbb
Indications

head and neck squamous cell carcinoma

Therapies

Methotrexate

Cetuximab

Docetaxel

Nivolumab

Age Groups: adult

No variant requirements are available.